The Congenital Hyperinsulinism Center was established in 1998, the first of its kind in the United States. We have treated more than 800 children with congenital HI, and performed more than 450 pancreatectomies — making our Center the largest and most active HI Center in the world.
Our experience, combined with unique expertise in areas such as gene research, surgery and innovative treatment strategies, puts us at the forefront of clinical care for congenital hyperinsulinism. CHOP sees 80 percent of all babies born in the United States who are diagnosed with HI.
Our specialists are pioneers in the diagnosis and treatment of congenital HI, offering groundbreaking approaches that have set the standards for care worldwide.
Our cure rate for focal hyperinsulinism is 95 percent; about 50 percent of children who require a pancreatectomy for HI are diagnosed with focal HI.
Our multidisciplinary team of experts includes pediatric endocrinologists, surgeons, radiologists, pathologists, anesthesiologists, nurses, social workers, researchers, speech and feeding therapists, and dieticians — all working together to provide specialized, patient-centered and seamless care for children with congenital HI and their families.
Since 2004, and under an FDA protocol, we have been performing the 18F-DOPA PET scan to identify focal HI lesions for the surgeons to remove. We have performed more than 230 18F-DOPA PET scans, by far the most of anyone in the world. This is only part of the innovative research being performed here at CHOP.
Compassionate, family-centered care
Each and every patient and family we care for is unique, and we aim to tailor our care for each child. We encourage parents to actively participate in their child’s treatment and the decision-making process.